Inovio Pharmaceuticals: Speculative Buy Thesis Hinges On INO-3107

Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check ...
TipRanks on MSN

FDA accepts Inovio’s BLA for INO-3107 review

Inovio Pharmaceuticals ( ($INO) ) has provided an announcement. On December 29, 2025, INOVIO announced that the U.S. Food and Drug Administration ...
Benzinga.com

Inovio Stock Sinks As FDA Pushes Back On Accelerated Approval For Rare Disease Drug

Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock fell Monday after the U.S. Food and Drug Administration accepted the company’s Biologics License Application (BLA) for INO-3107 but raised concerns tied ...
Investing.com South Africa

Inovio stock tumbles after FDA questions accelerated approval path

Investing.com -- Inovio Pharmaceuticals Inc (NASDAQ:INO) stock plunged 21% Monday after the FDA raised concerns about the company’s accelerated approval pathway for its RRP treatment candidate.

Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors

This was the stock's third consecutive day of losses.
Morningstar

FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from ...
Morningstar

INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review Expect to receive file acceptance by year end 2025 ...

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

Shares of Inovio Pharmaceuticals Inc. INO slid 3.11% to $1.56 Friday, on what proved to be an all-around great trading ...